Predicting the neurobehavioral side effects of dexamethasone in pediatric acute lymphoblastic leukemia

Lidewij T. Warris*, Erica L. T. van den Akker, Femke K. Aarsen, Marc B. Bierings, Cor van den Bos, Wim J. E. Tissing, Sebastiaan D. T. Sassen, Margreet A. Veening, Christian M. Zwaan, Rob Pieters, Marry M. van den Heuvel-Eibrink

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Scopus)

Abstract

Although dexamethasone is an effective treatment for acute lymphoblastic leukemia (ALL), it can induce a variety of serious neurobehavioral side effects. We hypothesized that these side effects are influenced by glucocorticoid sensitivity at the tissue level. We therefore prospectively studied whether we could predict the occurrence of these side effects using the very low-dose dexamethasone suppression test (DST) or by measuring trough levels of dexamethasone. Fifty pediatric patients (3-16 years of age) with acute lymphoblastic leukemia (ALL) were initially included during the maintenance phase (with dexamethasone) of the Dutch ALL treatment protocol. As a marker of glucocorticoid sensitivity, the salivary very low-dose DST was used. A post-dexamethasone cortisol level

Original languageEnglish
Pages (from-to)190-195
Number of pages6
JournalPsychoneuroendocrinology
Volume72
DOIs
Publication statusPublished - Oct-2016

Keywords

  • Acute lymphoblastic leukemia
  • Pediatrics
  • Dexamethasone
  • Dexamethasone suppression test
  • Neurobehavioral problems
  • Predictors
  • GLUCOCORTICOID-RECEPTOR POLYMORPHISMS
  • ADRENAL INSUFFICIENCY
  • SALIVARY CORTISOL
  • CHILDREN
  • CHILDHOOD
  • THERAPY
  • CORTICOSTEROIDS
  • MOOD
  • VARIABILITY
  • SENSITIVITY

Cite this